Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
| العنوان: | Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus |
|---|---|
| المؤلفون: | Annaswamy Raji, Hakima Hannachi, Annpey Pong, Steven G. Terra, Jie Liu, Steven B. Heymsfield, Silvina Gallo |
| المصدر: | Obesity (Silver Spring, Md.) |
| بيانات النشر: | John Wiley and Sons Inc., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), 030209 endocrinology & metabolism, Overweight, Placebo, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Diabetes mellitus, medicine, Humans, 030212 general & internal medicine, Obesity, Clinical Trials and Investigations, Adverse effect, Sodium-Glucose Transporter 2 Inhibitors, Nutrition and Dietetics, business.industry, Incidence (epidemiology), Type 2 Diabetes Mellitus, nutritional and metabolic diseases, Original Articles, Middle Aged, medicine.disease, Bridged Bicyclo Compounds, Heterocyclic, Blood pressure, Diabetes Mellitus, Type 2, Original Article, Female, medicine.symptom, business |
| الوصف: | OBJECTIVE This study aimed to evaluate ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. METHODS Data from three placebo-controlled, randomized, Phase 3 studies were pooled. Patients with baseline BMI ≥ 25 (1,377/1,544; 89%) were assessed with a stratification by BMI subgroup. RESULTS At week 26, reductions from baseline in glycated hemoglobin A1c (HbA1c), fasting plasma glucose, body weight (BW), and systolic blood pressure (SBP) were greater with ertugliflozin versus placebo. For placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg, respectively, least squares mean change was 0.1%, -0.8%, and -0.9% for HbA1c and -1.2 kg, -3.1 kg, and -3.2 kg for BW. HbA1c reductions were consistent across BMI subgroups. For ertugliflozin 5 mg and 15 mg, least squares mean change (placebo adjusted) in absolute BW was -1.4 kg and -1.2 kg for BMI 25 to |
| اللغة: | English |
| تدمد: | 1930-739X 1930-7381 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcfa12aaf948f93d09c4eaa5313315cTest http://europepmc.org/articles/PMC7217180Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3fcfa12aaf948f93d09c4eaa5313315c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1930739X 19307381 |
|---|